NanoViricides, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NNVC | COCP | IVVD | TVGN | INO | EVAX | |
|---|---|---|---|---|---|---|
| Market cap | 35.24M | 19.46M | 186.76M | 95.87M | 167.50M | 26.79M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.9 | -2.1 | -1.2 | — | -3.9 | -198.0 |
| Price/book | 3.7 | 13.3 | 1.0 | -1.4 | 30.6 | 2.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −27.41% | +2.88% | −61.71% | −75.61% | −27.51% | −47.70% |
| Today | −3.50% | −5.61% | +8.96% | −3.38% | −2.41% | +0.34% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NNVC news ›As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated – Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
“The importance of the NV-387 Oral Gummies treatment for this Ebola Bundibugyo virus disease cannot be understated, considering the potential of the disease for rapid spread and the heavy toll it is taking in affected areas in terms of…
NanoViricides Reports Positive Juvenile Safety Data for NV-387, But Going Concern Risk Persists
citybuzz - NanoViricides, Inc. (NYSE American: NNVC) on Tuesday reported positive results from a juvenile mouse study of its broad-spectrum antiviral drug NV-387, a finding that could support the drug’s a
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children This study is expected to pave the way for pediatric use of NV-387 in clinical trials in…
NanoViricides sets November 21 director election
Netflix Reports Q3 2026 Earnings: Revenue Rises 12% to $12.87 Billion, Operating Margin 34.6% Supermicro Provides First Quarter of Fiscal Year 2027 Preliminary Business Update INOVIO Announces Favorable Judgment in Litigation with VGXI,…
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Peraso Receives Production Order Exceeding $2.0 Million for 60 GHz Fixed Wireless Access Deployment HPE Spaceborne Computer to Power High Performance Computing and AI on the Moon GameSquare Announces The "Grand Theft Auto" Effect The…
NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials
citybuzz - NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced it will present at the NIBA 153rd Investment Conference on October 7, 2026,
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd Investment Conference in Fort Lauderdale,…
NanoViricides Advances Phase II Trial of Oral Ebola Treatment as Congo Outbreak Continues
citybuzz - NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebol
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net4
- citybuzz.co2
- digitaljournal.com1
- joplinglobe.com1
- rutlandherald.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.